Alnylam Pharma(CH:DUL)
CHFÂ 138.580.00 (0.00%)
CH:DUL
Alnylam Pharma financials statements
CHFÂ 138.58
At close:0.00 (0.00%)
Alnylam Pharma (DUL) Income Statement
0 Followers
Alnylam Pharma Income Statement
Last quarter (Q3 2026), Alnylam Pharma's total revenue was $1.46B, an increase of 16.74% from the same quarter last year. In Q3, Alnylam Pharma's net income was $2.17B. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 3.71B | $ 2.25B | $ 1.83B | $ 1.04B | $ 844.29M | |
| $ 3.04B | $ 1.92B | $ 1.52B | $ 868.60M | $ 704.14M | |
| $ 2.54B | $ 2.10B | $ 1.80B | $ 1.65B | $ 1.41B | |
| Depreciation and Amortization | $ 55.66M | $ 56.67M | $ 54.05M | $ 44.47M | $ 47.57M |
| $ 631.44M | $ -178.85M | $ -258.24M | $ -926.56M | $ -661.56M | |
| $ 501.58M | $ -176.88M | $ -282.18M | $ -785.07M | $ -708.65M | |
| $ -178.43M | $ -200.49M | $ -151.34M | $ -341.92M | $ -143.49M | |
| $ 323.15M | $ -377.38M | $ -433.52M | $ -1.13B | $ -852.14M | |
| $ 313.75M | $ -278.16M | $ -440.24M | $ -1.13B | $ -852.82M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.39 | $ -2.18 | $ -3.52 | $ -9.30 | $ -7.20 |
| Diluted EPS | $ 2.33 | $ -2.18 | $ -3.52 | $ -9.30 | $ -7.20 |
| Weighted Average Shares Outstanding | 131.00M | 127.65M | 124.91M | 121.69M | 118.45M |
| Weighted Average Shares Outstanding (Diluted) | 134.68M | 127.65M | 124.91M | 121.69M | 118.45M |
Currency in USD
